blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2303332

EP2303332 - ANTHRACYCLINE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS [Right-click to bookmark this link]
Former [2011/14]ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
[2014/36]
StatusNo opposition filed within time limit
Status updated on  06.11.2015
Database last updated on 07.10.2024
Most recent event   Tooltip10.08.2018Lapse of the patent in a contracting state
New state(s): PT		published on 12.09.2018  [2018/37]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080 / US
For all designated states
NERVIANO MEDICAL SCIENCES S.R.L.
Viale Pasteur, 10
20014 Nerviano (MI) / IT
[2011/14]
Inventor(s)01 / BERIA, Italo
c/o Nerviano Medical Sciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
02 / CARUSO, Michele
c/o Nerviano Medical Sciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
03 / FLYGARE, John, A.
c/o Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
04 / LUPI, Vittoria
c/o Nerviano Medical Sciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
05 / PEREGO, Rita
c/o Nerviano Medical Sciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
06 / POLAKIS, Paul
c/o Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
07 / POLSON, Andrew
c/o Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
08 / SALSA, Matteo
c/o Nerviano Medical Sciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
09 / SPENCER, Susan, D.
c/o Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
10 / VALSASINA, Barbara
c/o Nerviano MedicalSciences S.r.l.
Viale Pasteur 10
20014 Nerviano, MI / IT
 [2015/01]
Former [2011/14]01 / BERIA, Italo
c/o Nerviano Medical Sciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
02 / CARUSO, Michele
c/o Nerviano Medical Sciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
03 / FLYGARE, John, A.
c/o Genentech Inc. 1 DNA Way
South San Francisco, CA 94080 / US
04 / LUPI, Vittoria
c/o Nerviano Medical Sciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
05 / PEREGO, Rita
c/o Nerviano Medical Sciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
06 / POLAKIS, Paul
c/o Genentech Inc. 1 DNA Way
South San Francisco, CA 94080 / US
07 / POLSON, Andrew
c/o Genentech Inc. 1 DNA Way
South San Francisco, CA 94080 / US
08 / SALSA, Matteo
c/o Nerviano Medical Sciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
09 / SPENCER, Susan, D.
c/o Genentech Inc. 1 DNA Way
South San Francisco, CA 94080 / US
10 / VALSASINA, Barbara
c/o Nerviano MedicalSciences S.r.l. Viale Pasteur 10
20014 Nerviano, MI / IT
Representative(s)Kiddle, Simon John, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[N/P]
Former [2015/01]Kiddle, Simon John, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Former [2011/14]Kiddle, Simon John, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date09790394.214.07.2009
[2011/14]
WO2009US50537
Priority number, dateUS20080080944P15.07.2008         Original published format: US 80944 P
[2011/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010009124
Date:21.01.2010
Language:EN
[2010/03]
Type: A2 Application without search report 
No.:EP2303332
Date:06.04.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 21.01.2010 takes the place of the publication of the European patent application.
[2011/14]
Type: B1 Patent specification 
No.:EP2303332
Date:31.12.2014
Language:EN
[2015/01]
Search report(s)International search report - published on:EP23.12.2010
ClassificationIPC:A61K47/48, A61P35/00
[2011/14]
CPC:
A61K47/64 (EP,US); C07D498/14 (KR); C07K16/2863 (US);
A61K31/5383 (KR); A61K47/50 (KR); A61K47/6809 (EP,US);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP);
C07K2317/76 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/14]
Extension statesAL06.01.2011
BA06.01.2011
RS06.01.2011
TitleGerman:ANTHRACYCLINKONJUGATE, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ANTITUMORMITTEL[2014/36]
English:ANTHRACYCLINE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS[2014/36]
French:CONJUGUÉS DE DÉRIVÉS D ANTHRACYCLINE, PROCÉDÉ DE PRÉPARATION ASSOCIÉ ET UTILISATION COMME COMPOSÉS ANTITUMORAUX[2011/14]
Former [2011/14]ANTHRAZYKLIN-DERIVAT-KONJUGATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ANTITUMORALE VERBINDUNGEN
Former [2011/14]ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
Entry into regional phase06.01.2011National basic fee paid 
06.01.2011Designation fee(s) paid 
06.01.2011Examination fee paid 
Examination procedure06.01.2011Examination requested  [2011/14]
31.03.2011Amendment by applicant (claims and/or description)
03.12.2012Despatch of a communication from the examining division (Time limit: M04)
22.03.2013Reply to a communication from the examining division
04.03.2014Cancellation of oral proceeding that was planned for 11.03.2014
11.03.2014Date of oral proceedings (cancelled)
27.08.2014Communication of intention to grant the patent
14.11.2014Receipt of the translation of the claim(s)
18.11.2014Fee for grant paid
18.11.2014Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.12.2012
Opposition(s)01.10.2015No opposition filed within time limit [2015/50]
Fees paidRenewal fee
12.07.2011Renewal fee patent year 03
13.07.2012Renewal fee patent year 04
08.07.2013Renewal fee patent year 05
08.07.2014Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.07.2009
AT31.12.2014
BE31.12.2014
BG31.12.2014
CY31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
MK31.12.2014
MT31.12.2014
NL31.12.2014
PL31.12.2014
PT31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
SM31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
IE14.07.2015
LU14.07.2015
[2018/37]
Former [2018/30]HU14.07.2009
AT31.12.2014
BE31.12.2014
BG31.12.2014
CY31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
MK31.12.2014
MT31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
SM31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
IE14.07.2015
LU14.07.2015
Former [2017/38]HU14.07.2009
AT31.12.2014
BE31.12.2014
BG31.12.2014
CY31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
MT31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
SM31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
IE14.07.2015
LU14.07.2015
Former [2017/21]AT31.12.2014
BE31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
MT31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
IE14.07.2015
LU14.07.2015
Former [2016/33]AT31.12.2014
BE31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
IE14.07.2015
LU14.07.2015
Former [2016/24]AT31.12.2014
BE31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
LU14.07.2015
Former [2016/15]AT31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
LU14.07.2015
Former [2016/13]AT31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
MC31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
Former [2016/12]AT31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SI31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
Former [2015/49]AT31.12.2014
CZ31.12.2014
DK31.12.2014
EE31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
Former [2015/38]AT31.12.2014
CZ31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
IS30.04.2015
Former [2015/37]CZ31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
PL31.12.2014
RO31.12.2014
SE31.12.2014
SK31.12.2014
NO31.03.2015
GR01.04.2015
Former [2015/36]CZ31.12.2014
FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
RO31.12.2014
SE31.12.2014
NO31.03.2015
GR01.04.2015
Former [2015/29]FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
NL31.12.2014
SE31.12.2014
NO31.03.2015
GR01.04.2015
Former [2015/24]FI31.12.2014
HR31.12.2014
LT31.12.2014
LV31.12.2014
SE31.12.2014
NO31.03.2015
GR01.04.2015
Former [2015/23]FI31.12.2014
LT31.12.2014
NO31.03.2015
Former [2015/21]LT31.12.2014
NO31.03.2015
Former [2015/20]LT31.12.2014
Cited inInternational search[Y]EP0398305  (BRISTOL MYERS SQUIBB CO [US]) [Y] 4-9,14-16,21-55 * figures 1,2 *;
 [XDY]WO9202255  (ERBA CARLO SPA [IT]) [XD] 1-3,10-13,17-20 * example 13 * [Y] 4-9,14-16,21-55;
 [XY]EP0476408  (BRUNSWICK CORP [US]) [X] 1-3,10-13,17-20 * example III * [Y] 4-9,14-16,21-55;
 [Y]GB2315067  (PHARMACIA SPA [IT], et al) [Y] 4-9,14-16,21-55 * the whole document *;
 [XDY]US5776458  (ANGELUCCI FRANCESCO [IT], et al) [XD] 1-3,10-13,17-20 * examples 13-39; claim 1 * [Y] 4-9,14-16,21-55;
 [XY]WO2004067038  (IMMUNOMEDICS INC [US], et al) [X] 1-3,10-13,17-20 * paragraph [0055]; claim 2 * [Y] 4-9,14-16,21-55;
 [E]WO2009099741  (GENENTECH INC [US], et al) [E] 1-55* the whole document *;
 [XDY]  - HAMANN P R, "Monoclonal antibody-drug conjugates", EXPERT OPINION ON THERAPEUTIC PATENTS 200509 GB LNKD- DOI:10.1517/13543776.15.9.1087, (200509), vol. 15, no. 9, ISSN 1354-3776, pages 1087 - 1103, XP002606237 [XD] 1-3,10-13,17-20 * compound 3b * [Y] 4-9,14-16,21-55

DOI:   http://dx.doi.org/10.1517/13543776.15.9.1087
 [XY]  - KING H D ET AL, "BR96 CONJUGATES OF HIGHLY POTENT ANTHRACYCLINES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/S0960-894X(03)00375-5, (20030101), vol. 13, no. 13, ISSN 0960-894X, pages 2119 - 2122, XP001193826 [X] 1-3,10-13,17-20 * compound 3b * [Y] 4-9,14-16,21-55

DOI:   http://dx.doi.org/10.1016/S0960-894X(03)00375-5
 [YD]  - QUINTIERI LUIGI ET AL, "Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050215), vol. 11, no. 4, ISSN 1078-0432, pages 1608 - 1617, XP002576594 [YD] 1-55 * abstract *
 [Y]  - GARNETT M C, "Targeted drug conjugates: Principles and progress", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/S0169-409X(01)00227-7, (20011217), vol. 53, no. 2, ISSN 0169-409X, pages 171 - 216, XP002261805 [Y] 1-55 * figure 4 *

DOI:   http://dx.doi.org/10.1016/S0169-409X(01)00227-7
 [Y]  - ROBERT J ET AL, "PHARMACOKINETICS AND METABOLISM OF ANTHRACYCLINES", CANCER SURVEYS, OXFORD, GB, (19930101), vol. 17, no. 1, pages 219 - 252, XP000893095 [Y] 4-9,14-16,21-55 * the whole document *
Examination   - Stephen C Alley ET AL, "Antibody-drug conjugates: targeted drug delivery for cancer", Current Opinion in Chemical Biology, (20100801), vol. 14, no. 4, doi:10.1016/j.cbpa.2010.06.170, ISSN 1367-5931, pages 529 - 537, XP055042125

DOI:   http://dx.doi.org/10.1016/j.cbpa.2010.06.170
    - John M. Lambert, "Drug-conjugated antibodies for the treatment of cancer", British Journal of Clinical Pharmacology, (20130823), vol. 76, no. 2, doi:10.1111/bcp.12044, ISSN 0306-5251, pages 248 - 262, XP055113941

DOI:   http://dx.doi.org/10.1111/bcp.12044
by applicantUS3773919
 WO9321319
 EP0616812
 US5362852
 US5583024
 WO9704801
 US5674713
 US5700670
 US5821337
 WO0014228
 WO0148204
 WO0230268
 WO02054940
 WO02059377
 WO02064798
 WO02078524
 WO02086443
 WO02099122
 WO02098358
 WO02099074
 WO02102235
 WO03003906
 WO03016475
 WO03024392
 WO03025138
 WO03029421
 WO03042661
 WO03055443
 US2003134790
 US6602677
 US2003224454
 WO2004032842
 WO2004048938
 WO2004063362
 US2005107595
 US2005106644
 US2005276812
 US2008311134
 US7498298
 US7521541
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - DIJKE,P. ET AL., SCIENCE, (1994), vol. 264, no. 5155, pages 101 - 104
    - ONCOGENE, (1997), vol. 14, no. 11, pages 1377 - 1382
    - BIOCHEM. BIOPHYS. RES. COMMUN, (1999), vol. 255, no. 2, pages 283 - 288
    - NATURE, (1998), vol. 395, no. 6699, pages 288 - 291
    - GAUGITSCH, H.W. ET AL., J. BIOL. CHEM., (1992), vol. 267, no. 16, pages 11267 - 11273
    - CANCER RES., (2001), vol. 61, no. 15, pages 5857 - 5860
    - HUBERT, R.S. ET AL., CANCER RES., vol. 266, pages 593 - 602
    - LIANG ET AL., CANCER RES., (2000), vol. 60, pages 4907 - 12
    - GLYNNE-JONES ET AL., INT J CANCER., (20011015), vol. 94, no. 2, pages 178 - 84
    - HERMANSON, G.T., Bioconjugate Techniques, ACADEMIC PRESS, (1996), pages 234 - 242
    - GEOGHEGAN; STROH, BIOCONJUGATE CHEM., (1992), vol. 3, pages 138 - 146
    - YU, D. S. ET AL., J. UROL., (1988), vol. 140, page 415
    - SMITH, P. K. ET AL., ANAL. BIOCHEM., (1985), vol. 150, page 76
    - BRADFORD, M. M., ANAL. BIOCHEM., (1976), vol. 72, page 248
    - GALLEGO, J. ET AL., INT. J. CANCER, (1984), vol. 33, page 737
    - HAMBLETT ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 7063 - 7070
    - SANDERSON ET AL., CLIN. CANCER RES., (2005), vol. 11, pages 843 - 852
    - ISHIMI ET AL., JOUR. BIOL CHEM, (2001), vol. 276, no. 46, pages 42744 - 42752
    - CROUCH ET AL., J. IMMUNOL. METH., (1993), vol. 160, pages 81 - 88
    - CREE ET AL., ANTICANCER DRUGS, (1995), vol. 6, pages 398 - 404
 WO2009US31199
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.